Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Electrocardiol ; 57S: S34-S39, 2019.
Article in English | MEDLINE | ID: mdl-31526572

ABSTRACT

BACKGROUND: The clinical effectiveness of primary prevention implantable cardioverter defibrillator (ICD) therapy is under debate. It is urgently needed to better identify patients who benefit from prophylactic ICD therapy. The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD) completed in 2019 will assess this issue. SUMMARY: The EU-CERT-ICD is a prospective investigator-initiated non-randomized, controlled, multicenter observational cohort study done in 44 centers across 15 European countries. A total of 2327 patients with heart failure due to ischemic heart disease or dilated cardiomyopathy indicated for primary prophylactic ICD implantation were recruited between 2014 and 2018 (>1500 patients at first ICD implantation, >750 patients non-randomized non-ICD control group). The primary endpoint was all-cause mortality, and first appropriate shock was co-primary endpoint. At baseline, all patients underwent 12­lead ECG and Holter-ECG analysis using multiple advanced methods for risk stratification as well as documentation of clinical characteristics and laboratory values. The EU-CERT-ICD data will provide much needed information on the survival benefit of preventive ICD therapy and expand on previous prospective risk stratification studies which showed very good applicability of clinical parameters and advanced risk stratifiers in order to define patient subgroups with above or below average ICD benefit. CONCLUSION: The EU-CERT-ICD study will provide new and current data about effectiveness of primary prophylactic ICD implantation. The study also aims for improved risk stratification and patient selection using clinical risk markers in general, and advanced ECG risk markers in particular.


Subject(s)
Comparative Effectiveness Research , Death, Sudden, Cardiac , Defibrillators, Implantable , Death, Sudden, Cardiac/prevention & control , Electrocardiography , Europe , Humans , Multicenter Studies as Topic , Observational Studies as Topic , Prospective Studies , Treatment Outcome
2.
ESC Heart Fail ; 6(1): 182-193, 2019 02.
Article in English | MEDLINE | ID: mdl-30299600

ABSTRACT

AIMS: The clinical effectiveness of primary prevention implantable cardioverter defibrillator (ICD) therapy is under debate. The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD) aims to assess its current clinical value. METHODS AND RESULTS: The EU-CERT-ICD is a prospective investigator-initiated non-randomized, controlled, multicentre observational cohort study performed in 44 centres across 15 European Union countries. We will recruit 2250 patients with ischaemic or dilated cardiomyopathy and a guideline indication for primary prophylactic ICD implantation. This sample will include 1500 patients at their first ICD implantation and 750 patients who did not receive a primary prevention ICD despite having an indication for it (non-randomized control group). The primary endpoint is all-cause mortality; the co-primary endpoint in ICD patients is time to first appropriate shock. Secondary endpoints include sudden cardiac death, first inappropriate shock, any ICD shock, arrhythmogenic syncope, revision procedures, quality of life, and cost-effectiveness. At baseline (and prior to ICD implantation if applicable), all patients undergo 12-lead electrocardiogram (ECG) and Holter ECG analysis using multiple advanced methods for risk stratification as well as detailed documentation of clinical characteristics and laboratory values. Genetic biobanking is also organized. As of August 2018, baseline data of 2265 patients are complete. All subjects will be followed for up to 4.5 years. CONCLUSIONS: The EU-CERT-ICD study will provide a necessary update about clinical effectiveness of primary prophylactic ICD implantation. This study also aims for improved risk stratification and patient selection using clinical and ECG risk markers.


Subject(s)
Cardiomyopathy, Dilated/therapy , Death, Sudden, Cardiac/prevention & control , Defibrillators, Implantable , Primary Prevention/methods , Risk Assessment , Cardiomyopathy, Dilated/complications , Cardiomyopathy, Dilated/mortality , Death, Sudden, Cardiac/epidemiology , Death, Sudden, Cardiac/etiology , Electrocardiography , Europe/epidemiology , Follow-Up Studies , Humans , Patient Selection , Prospective Studies , Quality of Life , Survival Rate/trends , Treatment Outcome
3.
Europace ; 16(5): 689-97, 2014 May.
Article in English | MEDLINE | ID: mdl-24500787

ABSTRACT

AIMS: The OPTI-MIND study aims to collect 2-year clinical outcomes of pacemaker patients in real-world clinical practice, overall and according to patient characteristics and pacemaker settings. METHODS AND RESULTS: The present analysis of the OPTI-MIND study describes the programmed device settings after discharge from the pacemaker implant. The objective was to determine whether these settings fit recent guidelines for device-programmed physiological pacing based on the preservation of atrioventricular synchrony, avoiding unnecessary pacing, ensuring rate increase during exercise or preventing neurally mediated symptoms. A total of 1740 patients were enroled at 68 centres worldwide. Baseline patient characteristics and device programming settings are available in 1674 of 1740 patients (96%). Guidelines to ensure physiological pacing were followed in 41% of patients: in patients with sinus node disease (SND), and without atrioventricular block (AVB), device programming could have led to unnecessary right ventricular pacing in 38% of patients. In SND patients with chronotropic incompetence, assisted rate increase during exercise was not programmed in 42% of patients. In 11% of patients with AVB, atrioventricular (AV) synchrony was not pursued; the main drivers being advanced age and history of atrial fibrillation. Patients with both SND and AVB were generally programmed physiologically (87%). CONCLUSION: The present analysis showed that frequent deviations occurred when comparing the device settings at discharge from the pacemaker implant in clinical practice to the available guidelines on pacing mode selection. Analysis of 2-year outcomes in the OPTI-MIND study will provide an insight into whether specific physiological settings could improve the quality of pacing with a positive effect on patient outcome.


Subject(s)
Atrial Fibrillation/therapy , Atrioventricular Block/therapy , Cardiac Pacing, Artificial/methods , Pacemaker, Artificial , Sick Sinus Syndrome/therapy , Aged , Aged, 80 and over , Cardiac Pacing, Artificial/standards , Cohort Studies , Female , Guideline Adherence/statistics & numerical data , Humans , Male , Middle Aged , Practice Guidelines as Topic , Prospective Studies , Treatment Outcome
4.
Europace ; 13(6): 902-4, 2011 Jun.
Article in English | MEDLINE | ID: mdl-20876600

ABSTRACT

The implantable cardioverter-defibrillator (ICD) has revolutionized the treatment of patients at risk of sudden cardiac death due to ventricular arrhythmias. Repeated studies have shown them to increase overall survival rates in patients with congestive heart failure or previous myocardial infarction and left ventricular dysfunction. We present a rare case of out-of-hospital ICD heat dissipation due to rapid battery discharge preceded by an audible popping noise.


Subject(s)
Defibrillators, Implantable/adverse effects , Equipment Failure , Heart Failure/therapy , Hot Temperature , Outpatients , Humans , Male , Middle Aged , Quality Control , Risk Factors , Tomography, X-Ray Computed , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...